Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on EUROPEAN WEALTH GROUP LTD. We currently have 6 research reports from 3 professional analysts.
|27Feb17 07:00||RNS||Issue of Equity|
|10Feb17 07:00||RNS||Trading Update|
|17Jan17 07:00||RNS||Issue of Equity|
|18Oct16 07:00||RNS||Change of Adviser|
|07Oct16 11:18||RNS||RESULTS OF FUNDRAISING AND DIRECTORS' DEALINGS|
|07Oct16 07:00||RNS||PROPOSED ACQUISITION OF CERTAIN ASSETS OF TOWRY AM|
|14Sep16 07:00||RNS||Director Dealing|
Frequency of research reports
Research reports on
EUROPEAN WEALTH GROUP LTD
EUROPEAN WEALTH GROUP LTD
European Wealth Group – Planning for Growth
22 Feb 17
European Wealth Group (EWGL), the integrated financial planning and wealth management group, is due to release full year financial results for the 12 months to December 2016 in late March or early April 2017. Ahead of those results we have reviewed the Group’s recent progress and looked at what can reasonably be expected for business development and growth over the medium term.
Small Cap Breakfast
10 Feb 17
Saffron Energy— Schedule One. Italian Oil and Gas play . Expected admission 24 Feb. Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb. Arix Bioscience — Intention to float on the main market from the global healthcare and life science company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.
Panmure Morning Note 22-09-15
22 Sep 15
First half revenues of £3.9m were in line with expectations, +90% YOY impacted by an acquisition and +13% like for like. Total AUM rose 30% YOY to £1.08bn. EBITDA in H115 was effectively at break-even level owing to on-going investment in the business but we expect strong growth as EWG expands. We foresee an upgrade to profit forecasts from two further accretive acquisitions made since June. EWG has substantial upside in profits from leveraging up its AUM organically and through consolidation. We remain buyers of the shares for growth with an unchanged SOTP based 140p price target.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.